Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > 01177 SINO BIOPHARM > Detailed Quotes

01177 SINO BIOPHARM

Watchlist
4.830
-0.080-1.63%
Trading Session  01/30 14:00 CCT
High
4.930
Open
4.900
Turnover
129.93M
Low
4.790
Pre Close
4.910
Volume
26.83M
Market Cap
90.87B
P/E(TTM)
9.66
52wk High
5.550
Shares
18.81B
P/E(Static)
5.08
52wk Low
3.520
Float Cap
90.87B
Bid/Ask %
3.44%
Historical High
11.060
Shs Float
18.81B
Volume Ratio
1.82
Historical Low
-0.480
Dividend TTM
0.1
Div Yield TTM
0.08
P/B
2.57
Dividend LFY
2.07%
Div Yield LFY
1.66%
Turnover Ratio
0.14%
Amplitude
2.85%
Avg Price
4.842
Lot Size
1000
Float Cap
90.87B
Bid/Ask %
3.44%
Historical High
11.060
Shs Float
18.81B
Volume Ratio
1.82
Historical Low
-0.480
Dividend TTM
0.1
P/B
2.57
Dividend LFY
2.07%
Turnover Ratio
0.14%
Amplitude
2.85%
Avg Price
4.842
Lot Size
1000
Price Forecast

News

Comment

Company Overview More
China Biopharmaceutical Co., Ltd. (the “Company” or “China Biopharmaceutical”) and its subsidiaries (the “Group”) is a leading innovative research and development (“R&D”) driven pharmaceutical group in the People's Republic of China (“China”). Its business covers various pharmaceutical R&D platforms, intelligent production and a strong sales system throughout the entire industry chain. Its products include a variety of biopharmaceuticals and chemicals, and have an advantage in many promising treatment fields such as tumors, liver disease, orthopedic and respiratory diseases. In order to continuously enhance the competitiveness of enterprises, the Group attaches great importance to R&D and innovation, leads the industry in R&D investment and product innovation capabilities, and actively develops extensive cooperation with famous pharmaceutical research institutions and enterprises at home and abroad, with the aim of achieving ecological industrialization of the world's most advanced technology to benefit humanity as soon as possible. The Group also grasps technology and policy trends, focuses on the linkage and expansion of its main business, and comprehensively lays out a healthy development strategy. At the same time, it actively uses new technologies and means such as big data, artificial intelligence and technology finance to continuously improve enterprise management and R&D, production and marketing efficiency. The Group has obtained the standard certificate for pharmaceutical production quality management (“GMP”) issued by the China Drug Administration (“China Drug Administration”). The dosage forms include high-volume injections, small-volume injections, non-PVC co-extruded film injections, capsules, tablets, powders and granules. In addition, the Group has also obtained the GMP capsule health food certificate issued by the Jiangsu Provincial Department of Health. The main subsidiaries of the Group are Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“Chia Tai Tianqing”), Beijing Ted Pharmaceutical Co., Ltd. (“Beijing Tide”), Nanjing Chia Da Tianqing Pharmaceutical Co., Ltd. (“Nanjing Chia Da Tianqing”), Jiangsu Chia Da Fenghai Pharmaceutical Co., Ltd. (“Jiangsu Chia Da Qingjiang”), Chia Tai Pharmaceutical (Qingdao) Co., Ltd. (“Chia Tai Qingdao”), Lianyungang Runzhong Pharmaceutical Co., Ltd. (“Lianyungang Runzhong”) General Pharmaceutical Co., Ltd. (“Shanghai GM”) is a high-tech enterprise . Furthermore, Nanjing Zhengda Tianqing, Jiangsu Zhengda Qingjiang, and Jiangsu Zhengda Fenghai were recognized by the Jiangsu Provincial Department of Science and Technology as “Jiangsu Anti-tumor and Cardiovascular Phytochemical Pharmaceutical Formulation Engineering Technology Research Center”, “Orthopedic Pharmaceutical Formulation Engineering Technology Research Center”, and “Parenteral Nutrition Engineering Technology Research Center” respectively. The Chia Tai Tianqing R&D Center is a “postdoctoral research workstation” granted by the Chinese Ministry of Personnel. It is the only “novel liver disease drug engineering technology research center” in China. Beijing Tide once again obtained GMP certification for foreign pharmaceutical companies from Japan's Ministry of Health, Labor, and Welfare in December 2012. Japanese pharmaceutical companies can entrust Beijing Ted with the production and export of sterile pharmaceutical preparations being developed and marketed in Japan to Japan.
CEO: Qirun Xie
Market: Hong Kong motherboard
Listing Date: 09/29/2000
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist